{"id":16,"date":"2025-12-03T02:24:48","date_gmt":"2025-12-03T02:24:48","guid":{"rendered":"https:\/\/greengenes.org\/?page_id=16"},"modified":"2026-10-14T23:35:13","modified_gmt":"2026-10-14T23:35:13","slug":"about-us","status":"publish","type":"page","link":"https:\/\/greengenes.org\/?page_id=16","title":{"rendered":"About Us"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Michael Shipman<\/strong>, CEO of Green Gene Therapeutics, is a researcher with an M.S. in Biotechnology from Syracuse University. He works in Cornell University\u2019s postharvest research group, and his work integrates plant tissue culture, phytochemistry, molecular genetics, and climate-driven disease ecology. As a graduate research assistant with SUNY ESF\u2019s American Chestnut Restoration Project, he contributed to the development of the first transgenic American beech and to pathogen-resistance work in chestnut. At Syracuse his work included rye grass transformations. His research focuses on plant-derived compounds, including apple and root derivatives, that modulate human pain pathways and vascular function, and on therapeutic food and delivery innovation. He is an author of Plants for Pain: 33 Analgesics<\/em>.<\/p>\n\n\n\n

Through Green Gene Therapeutics, Michael is developing natural-delivery approaches to chronic illness management and disease prevention. He also consults on scientific and career networking and organizes outreach events such as Skydiving for Science, which raises awareness of aeromicrobiology and pathogen dispersal, including Coccidioides<\/em> species, which cause Valley Fever.<\/p>\n\n\n\n

Michael is an advocate of the UK’s Live Well with Pain’s Ten Footsteps and is expanding into pain science education coaching. His coaching covers healthy lifestyle change, progress tracking, the science behind each client\u2019s pain, and helping clients describe their pain clearly to their clinicians.<\/p>\n\n\n\n

Michael Shipman | LinkedIn<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Andrew Snowball<\/strong>, Chair of the Board, is a Chartered Civil Engineer and experienced industry leader who brings versatility, engineering acumen, and a passion for learning to his role as Board Chair of Green Genes Therapeutics. Alongside his professional career, Andrew serves as Regional Chair for the Institution of Structural Engineers and as a trustee for a local charity, contributing his governance and leadership expertise to organisations that create meaningful impact. His analytical mindset and broad perspective help guide Green Genes through its early development with clarity, structure, and purpose.<\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Professor Paul Chazot FBPhS<\/strong>, Science Advisor, holds a Personal Chair in Pharmacology, Durham University (H factor=48). He is a Fellow of the British Pharmacological society, Past President, European Histamine Research Society, Fellow of the Durham Institute of Research, Development, and Invention, Northern Health Science Alliance (NHSA) Repurposing Medicines Network Representative, Academic Partner,  Nevrargenics (www.nevrargenics.com<\/a>), Vice Chair, EU COST action BM0806, Chair, International Union of Pharmacological Societies Subcommittee, Past Committee officer, British Neuroscience Association, Founder and Director, Wolfson Research Institute for Health an Wellbeing Pain Challenge Academy, International Concussion Alliance, Head for Change & Repercussion Groupings member. ARUK Research Committee; Durham Dementia Strategy Implementation Group member, Academic partner for www.livewellwithpain.co.uk<\/a> and  Company Director, Cerebrovia Therapeutics Ltd.<\/p>\n\n\n\n

His research group focuses on the development of non-invasive imaging and biomarker diagnostic toolbox, and identification, characterisation and validation of novel drug targets, and  a range of natural plant and synthetic drug-based, and infra-red light-based treatments for the major chronic CNS pathologies, and a first -line treatment for post-concussion syndrome.<\/p>\n","protected":false},"excerpt":{"rendered":"

Michael Shipman, CEO of Green Gene Therapeutics, is a researcher with an M.S. in Biotechnology from Syracuse University. He works in Cornell University\u2019s postharvest research group, and his work integrates plant tissue culture, phytochemistry, molecular genetics, and climate-driven disease ecology. As a graduate research assistant with SUNY ESF\u2019s American Chestnut Restoration Project, he contributed to […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-16","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/greengenes.org\/index.php?rest_route=\/wp\/v2\/pages\/16","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/greengenes.org\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/greengenes.org\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/greengenes.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/greengenes.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16"}],"version-history":[{"count":5,"href":"https:\/\/greengenes.org\/index.php?rest_route=\/wp\/v2\/pages\/16\/revisions"}],"predecessor-version":[{"id":122,"href":"https:\/\/greengenes.org\/index.php?rest_route=\/wp\/v2\/pages\/16\/revisions\/122"}],"wp:attachment":[{"href":"https:\/\/greengenes.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}